Euro HIV Meet 2020 cordially invite all the Researchers, Academicians, Students and Business professionals in the field of STI, STD, and HIV/AIDS to the “European Summit on HIV, STD and STI” scheduled on August 19-20, 2020 Webinar. The conference includes prompt Keynote Presentations, Oral Talks, Poster Presentations, Workshops and Exhibitions. As said “Prevention is better than cure”, we also believe that sharing the knowledge and discussing about the field of infectious diseases which have become progressively important to Public Health is the major aspects to which everyone should be aware of.
Theme: Creating New Strategies to Prevent HIV/AIDs, STDs and STIs in the time of COVID-19
We would like to organize this conference with your support to gather all the researchers in a single platform, hope we will be honoured with your support to organize Euro HIV Meet 2020 in a grand level, your support will be the key of success for our conference.
Why to Attend?
Euro HIV Meet 2020 provides two days discussions on methods and schemes related to “European Summit on HIV, STD and STI” as well as exploring new ideas and perceptions on a universal scale. This two day event provides a flawless platform for leading Scientists, Researchers, Scholars, Practitioners, Health Care Experts, Treatment providers, Public Health Professionals, and Community health educators, Members of Academia, Allied Health Professionals, Nurse Practitioners, Pharmacists, Physicians, Physician Assistants, Social Workers, Student Researchers, Faculties, STD-AIDS Associations and Societies from different part of the countries.
Target Audience:
-
Immunologists
-
Radiologists
-
Microbiologists
-
Bacteriologists
-
Virologists
-
STD-AIDS associations and societies
-
Epidemiologists
-
Public Healthcare Professionals
-
Research scholars
-
Medical colleges
-
Infectious Diseases Researchers
-
Viral Diseases Researchers
-
Nursing care Professionals
To submit your abstract, CLICK HERE
To view the registration prices, CLICK HERE
We look forward to see your benign presence with active contribution and support to make this event successful once more.
___________________________________________________________________________________________
PARTICIPATION Details: Euro HIV Meet 2020 provides the participants with different modes or ways to participate under ACADEMIC /STUDENT /BUSINESS Category
-
KEYNOTE SPEAKER: Talk for 45-50 minutes
-
SPEAKER (Oral Presentation): 25-30 minutes
-
SPEAKER (Workshop): 45-50 minutes (more than 1 participant can present)
-
SPEAKER (Symposium): more than 45 minutes (more than 1 participant can present)
-
DELEGATE: Have access to all the sessions with all the benefits of registration
-
POSTER PRESENTER: Can present a poster and enjoy attending all the sessions
-
REMOTE ATTENDANCE: Can participate via VIDEO presentation or E-poster presentation
-
EXHIBITOR: Can exhibit his/her company products by booking exhibitor booth
-
MEDIA PARTNER: Company Logo and description will be uploaded on website
-
SPONSOR: Company Logo and description will be uploaded on website and conference book
-
COLLABORATOR: Company Logo and description will be uploaded on website
PARTICIPATION BENEFITS:
-
This Live conference is accredited with CPD credits.
-
Attend Keynote Presentation by world’s most eminent researchers
-
Access to all the sessions for 2 days
-
Get IOCM certificate
-
Get worldwide acknowledgment to your profile and Research
-
Get your abstracts published with unique DOI in International Journals
-
Get up to 50% discounts for publishing your entire article in our open access International Journals
-
Get Handbooks, Conference kits, Lunch for 2 days, Participation Certificate
-
Get an access to the network with eminent personalities from worldwide
___________________________________________________________________________________________
Antiretroviral therapy (ART) is recommended to treat HIV infection. People on ART take a combination of HIV medications every day. ART can’t cure HIV infection, but HIV medicines help individuals with HIV live longer, healthier lives. HIV medicines can also decrease the risk of HIV transmission. HIV diagnostics market size was valued at USD 2.9 billion in 2017 and is expected to witness 8.7% CAGR from 2018 to 2024.
Increasing prevalence of HIV infection worldwide will majorly boost HIV diagnostics market growth over the forecast period. HIV infection is one of the leading causes of morbidity and mortality. As per the UNAIDS’s data more than 36.7 million people across the globe were living with HIV in 2017. Around 1.8 million children aged below 15 years had HIV infection. Additionally, many were infected by their HIV-positive mothers during pregnancy, child birth or breast-feeding. Growing incidences of AIDS especially in the developing and underdeveloped economies will offer several growth opportunities in HIV diagnostics resulting in industry growth.
HIV Drug Market Analysis:
Human immunodeficiency virus (HIV) is one of the most infectious diseases with around 36.7 million people suffering by the end of 2015, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS). Global HIV Drug Market was valued at $20,448 million in 2015 and is expected to garner $26,458 million by 2022. In 2017 the global HIV drugs market exceeded a value of US$ 17 Billion. Looking forward, the market value is expected to reach nearly US$ 21 Billion by 2023, expanding at a CAGR of more than 3% during 2018-2023.
HIV Infected Death Rate:
7, 80, 000 people died of HIV-related illnesses worldwide in 2018. Expanded access to antiretroviral therapy (ART) and a declining incidence of HIV infections have led to a steep fall globally in the number of adults and children dying from HIV-related causes. The estimated 770 000 people dying from HIV globally in 2018 were 56% fewer than in 2004 (the peak) and 33% fewer than in 2010 in spite of a period of substantial population growth in many high burden countries.
Nevertheless, there is no room for complacency. Countries need to live up to their commitment to end the AIDS epidemic as a public health threat by 2030 - a target included in the 2030 Agenda for Sustainable Development adopted by the United Nations General Assembly in September 2015. The immediate challenge is to reach the Fast-Track targets for 2020, as HIV-related deaths are still unacceptably high.
Global Data:
Since the beginning of the HIV epidemic, more than 70 million individuals were infected approximately with the HIV and about 35 million people died of HIV. Universally, 36.9 million people are living with HIV at the end of 2017. An expected 0.8% of adults aged 15–49 years affected with HIV, although the burden of the epidemic continues to vary considerably between countries and regions. The WHO African region remains most severely affected, with nearly 1 in every 25 adults (4.1%) living with HIV and accounting for nearly two-thirds of the people living with HIV worldwide.
Major STD-HIV/AIDS Associations around the Globe:
-
European AIDS Clinical Society (EACS), Belgium
-
AIDS Action Europe (AAE), Berlin
-
International AIDS Society, Switzerland
-
United Nations Programme on HIV and AIDS (UNAIDS)
-
British HIV Association (BHIVA)
-
Deutsche AIDS Gesellschaft, Germany
-
International Union against Sexually Transmitted Infections (IUSTI)
-
European Society for Immunodeficiency’s
-
Association of Nurses in AIDS Care
-
HIV.gov, USA
-
American Sexually Transmitted Diseases Association (ASTDA)
-
International Society for Infectious Diseases
-
Centers for AIDS Research (CFAR)
-
Canadian Public Health Association (CPHA)
-
American Sexually Transmitted Diseases Association (ASTDA)
-
Solidarity and Action against the HIV Infection in India (SAATHII)
-
Australian Federation of AIDS Organisations (AFAO)
-
Indian Association for the Study of STDs & AIDS (IASSTD)
STD-HIV/AIDS Research Universities:
-
University of Cardenal Herrera, Spain
-
University of Oxford, United Kingdom
-
University of Cukurova, Turkey
-
University Hospital Marqués de Valdecilla, Spain
-
Goethe University Frankfurt, Germany
-
University of British Columbia, Canada
-
University of Maryland Medical Center, Spain
-
Texas A&M University- Veterinary Medicine and Biomedical Sciences, USA
-
National Institute for Infectious Diseases Lazzaro Spallanzani, Italy
-
San Raffaele Scientific Institute, Italy
-
Pompeu Fabra University, Spain
-
Duke University, USA
-
North-western University, USA
-
Harvard University, USA
-
University of Rochester Medical Center, United Kingdom
-
UCL Institute of Epidemiology and Health care
-
University of California, USA
-
Beth Israel Medical Center, Israel
-
New York University, USA
-
University of Liverpool, USA
-
Imperial College London, United Kingdom
-
University of Barcelona, Spain
Pharma Companies in Italy:
-
Fidia Farmaceutici
-
Angelini
-
Dipharma
-
Newron Pharmaceuticals
-
Charles River Laboratories
-
Silicon Biosystems
-
Adare Pharmaceuticals
-
Integra LifeSciences
-
Altheia Science
-
Holostem Tarapie Avanzate
-
NEURO-ZONE
-
Genenta Science
-
Integra LifeSciences
-
Teleflex Medical
